Articles related to WOMEN'S HEALTH

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

Beyond the strong recommendation for bisphosponates as initial medical therapy in postmenopausal women with osteoporosis, the updated guidelines also suggest (not recommend) denosumab as second line therapy in women, bisphosphonates for osteoporosis in men, and romosozumab in women with very high risk of fractures. For the complete updated guideline, see Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.

After 5 years of denosumab therapy, this patient has had no fractures and bone density scores have improved. You plan to discontinue denosumab. What else should be done?

In this on-demand webinar, a trio of Roswell Park Comprehensive Cancer Center experts share their wisdom on ovarian, cervical, and endometrial cancers. Dr. Emese Zsiros, Chair of Gynecologic Oncology, hosts the event with presenters Drs. Karen McLean and Katherine LaVinge Mager, Associate Professor of Oncology and Assistant Professor of Oncology in the Department of Gynecologic Oncology, respectively.

This broad review of recent studies in women’s health topics aims to help the primary care physician in discussing and guiding therapy for women in topics from cardiovascular disease to pelvic pain. The review covers such questions as: How does migraine with aura affect CVD risk in women? How do you respond to patient questions about fracture risk and bisphosphonates? Are antidepressants safe for women who are considering pregnancy? Is gabapentin effective for chronic pelvic pain?

A UK study reports that a history of irregular menstrual cycle was associated with higher risk for afib in women. A finding from the Vitamin D and Omega 3 Trial (VITAL) Rhythm Study reveals that when controlled for height and body size, women are at higher risk than men for afib, suggesting that biological sex and body size account for much of the protective effect of female sex. And as separately reported, early rhythm control is associated with lower risk for CV events as compared to usual care.